AtaiBeckley (ATAI) Non-Current Deferred Tax Liability (2024 - 2025)
AtaiBeckley (ATAI) recorded quarterly Non-Current Deferred Tax Liability of $17.8 million in Q4 2025, up 17.63% quarter-over-quarter from $15.1 million in Q4 2024, and up 17.63% on a YoY basis from $15.1 million in Q4 2024.
AtaiBeckley (ATAI) Non-Current Deferred Tax Liability (2024 - 2025) Analysis & Trends
AtaiBeckley's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $17.8 million for Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability rose 17.63% year-over-year to $17.8 million; the TTM figure through Dec 2025 stood at $17.8 million (up 17.63% YoY), while the FY2025 annual figure was $17.8 million, up 17.63% from the prior year.
- Non-Current Deferred Tax Liability was $17.8 million for Q4 2025 at AtaiBeckley, up from $15.1 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $17.8 million in Q4 2025 to a low of $15.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.82 Mn |
| Dec 31, 2025 | 17.82 Mn |
| Dec 31, 2024 | 15.15 Mn |
| Dec 31, 2024 | 15.15 Mn |